Clinical Studies Exploring Low-Dose Injection Activity of 18F-FDG Using Total-Body PET/CT
| Year | Author | Patients (n) | Population | Disease | Injection dose | Conclusion |
|---|---|---|---|---|---|---|
| 2022 | Chen et al. (12) | 100 | Pediatric patients | Oncology | Half dose (1.85 MBq/kg) | Sufficient image quality and lesion conspicuity could be maintained at fast acquisition time of 1 min with half-dose activity of 18F-FDG |
| 2022 | He et al. (17) | 46 | Adults | Oncology | Half dose (1.85 MBq/kg) | Half dose of 18F-FDG with acquisition times ≥ 5 min could be applied in clinical practice |
| 2021 | Tan et al. (13) | 56 | Adults | Lung cancer | Half dose (1.85 MBq/kg) | Total-body PET/CT with half dose of 18F-FDG in 2 and 4 min achieved comparable image quality to conventional PET/CT |
| 2022 | Hu et al. (18) | 30 | Adults | Oncology | Ultralow dose (0.37 MBq/kg) | Ultralow 18F-FDG activity with 8-min acquisition in total-body PET/CT can achieve acceptable image quality equivalent to that in full-activity group after 2-min acquisition |
| 2022 | Abdelhafez et al. (54) | 30 | Adults | AIA | Ultralow dose (78.1 ± 4.7 MBq) | Systemic joint evaluation in AIA (and non-AIA) is feasible with total-body PET/CT and ultra-low-dose 18F-FDG protocol |
| 2022 | Tan et al. (55) | 62 | Adults | CRC | Ultralow dose (0.37 MBq/kg) | Total-body PET/CT with ultralow dose of 18F-FDG can maintain satisfactory image quality and lesion detectability in CRC |
| 2023 | Tan et al. (56) | 30 | Adults | Oncology | Ultralow dose (0.37 MBq/kg) vs. half dose (1.85 MBq/kg) | Total-body PET/CT with ultra-low-dose activity of 18F-FDG, corresponding acquisition time of 8 min, provides acceptable image quality and lesion detection |
AIA = autoimmune inflammatory arthritis; CRC = colorectal cancer.